688302 Hinova Pharmaceuticals Inc.
- 26.50
- +0.23+0.88%
Hinova Pharmaceuticals Inc. News
Hinova Pharmaceuticals (SHSE:688302) Is In A Good Position To Deliver On Growth Plans
We can readily understand why investors are attracted to unprofitable companies. For example, although software-as-a-service business Salesforce.com lost money for years while it grew recurring reve
Haichuang Pharmaceutical (688302.SH): PROTAC drug under development HP518 will release clinical data at the 2024 American Society of Clinical Oncology Annual Meeting
Zhitong Finance App News, Haichuang Pharmaceutical (688302.SH) announced that clinical research data on the innovative drug HP518 developed by PROTAC independently developed by the company will be released at the 2024 American Society of Clinical Oncology (ASCO) annual meeting. HP518 is an oral, targeted proteolytic chimera (PROTAC) drug independently developed by the company to treat patients with advanced prostate cancer (mCRPC).
Guo Hong, chief medical officer and core technician of Haichuang Pharmaceutical (688302.SH), left office
Haichuang Pharmaceutical (688302.SH) announced that Guo Hong, the company's chief medical officer and core technical officer, recently due to personal reasons...
Haichuang Pharmaceutical (688302.SH) announced first-quarter results with a net loss of 47.21 million yuan
According to the Zhitong Finance App, Haichuang Pharmaceutical (688302.SH) disclosed its report for the first quarter of 2024. During the reporting period, the company achieved a revenue of 0 yuan; a net profit loss of 47.21 million yuan; and a loss of 52.72 million yuan after deducting non-net profit. Basic earnings per share - $0.48.
Haichuang Pharmaceutical (688302.SH) reported 2023 annual results, unrealized revenue, net loss of 294 million yuan
Haichuang Pharmaceutical (688302.SH) released its 2023 annual report. The company did not achieve operating income during the reporting period;...
Hinova Pharma Gets Nod to Trial HP501 Tablets; Shares Down 3%
Hinova Pharmaceuticals (SHA:688302) will conduct clinical trials on HP501 extended-release tablets after receiving approval from China's National Medical Products Administration, the company said in i
Haichuang Pharmaceutical (688302.SH): Clinical trial of HP501 extended-release tablets approved
Haichuang Pharmaceutical (688302.SH) issued an announcement. The company received the approval and issuance of “Drugs...” from the State Drug Administration
Haichuang Pharmaceutical (688302.SH) will list and circulate 994,400 restricted shares on April 12, 2024
Zhitong Finance App News, Haichuang Pharmaceutical (688302.SH) announced that the restricted shares listed and distributed are the company's initial public offering of restricted shares, involving 1 shareholder, CITIC Securities Investment Co., Ltd., an alternative investment subsidiary established by the sponsor in accordance with law. The corresponding number of shares is 994,400 shares, accounting for 1.0002% of the company's total share capital, and will be listed and circulated on April 12, 2024.
Hinova Pharmaceuticals Inc.'s (SHSE:688302) Market Cap up CN¥384m Last Week, Benefiting Both Individual Investors Who Own 41% as Well as Insiders
Key Insights Hinova Pharmaceuticals' significant individual investors ownership suggests that the key decisions are influenced by shareholders from the larger public The top 15 shareholders own 50%
Hinova Pharmaceuticals Gets Nod to Trial HP537 Tablets
Hinova Pharmaceuticals (SHA:688302) plans to conduct clinical trials on the HP537 tablets as a treatment for patients with hematological malignancies. China's National Medical Products Administration
Haichuang Pharmaceutical (688302.SH): Clinical trial of HP537 tablets to treat hematological malignancies approved
Zhitong Finance App News, Haichuang Pharmaceutical (688302.SH) issued an announcement. Recently, the company received the “Drug Clinical Trial Approval Notice” approved and issued by the Drug Evaluation Center of the State Drug Administration, agreeing to carry out clinical trials with HP537 tablets for “hematological malignancies.” HP537 tablets are mainly used to treat hematologic malignancies, including but not limited to multiple myeloma (MM), non-Hodgkin's lymphoma (NHL), acute myeloid leukemia (acu)
Haichuang Pharmaceutical (688302.SH) issued a forecast loss and is expected to have a net loss of 272 million yuan to 326 million yuan in 2023
Haichuang Pharmaceutical (688302.SH) released its 2023 annual results forecast and is expected to return to 2023...
Is Hinova Pharmaceuticals (SHSE:688302) Using Debt Sensibly?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the permanent loss of capital.' So it seems the smart money knows that debt - which is usu
Haichuang Pharmaceutical (688302.SH): Yingchuang Dynamics reduced its shareholding by 1.0183%
Gelonghui, January 12丨Haichuang Pharmaceutical (688302.SH) announced that the company recently received a “Notice Letter on the Expiration of the Stock Reduction Plan” from Yingchuang Power. As of January 11, 2024, the time range for this holdings reduction plan has expired. During the implementation of the current holdings reduction plan, Yingchuang Power reduced its holdings by a total of 1,008,303 shares, accounting for 1.0183% of the company's total share capital.
Yingchuang Power, a shareholder of Haichuang Pharmaceutical (688302.SH), reduced its holdings of the company by 1.02%
Haichuang Pharmaceutical (688302.SH) issued an announcement. The company received shareholder Yingchuangdong on December 29, 2023...
Haichuang Pharmaceutical (688302.SH): Clinical trial of HP518 tablets to treat prostate cancer completed the first patient enrollment
Haichuang Pharmaceutical (688302.SH) announced that HP518 tablets independently developed by the company are used to treat metastatic disease...
Haichuang Pharmaceutical (688302.SH): HP537 received a notice of acceptance of clinical trial applications
Gelonghui (688302.SH) announced on December 10丨Haichuang Pharmaceutical () announced that the company has received the “Notice of Acceptance” approved and issued by the State Drug Administration. HP537 tablets developed independently by the company are used to treat hematological malignancies, including but not limited to multiple myeloma (multiple myeloma, MM), non-Hodgkin's lymphoma (NHL), and acute myeloid leukemia (acute myeloidleukemia, AML), bone marrow Dysproliferative syndrome (
Hinova Pharmaceuticals Gets US FDA's Nod to Conduct Phase II Clinical Trial on HP501 Tablets
Hinova Pharmaceuticals (SHA:688302) will conduct the phase 2 clinical trial for HP501 extended-release tablets in the US after receiving approval from the country's Food and Drug Administration. The C
Haichuang Pharmaceutical (688302.SH): Application for phase II clinical trial of HP501 sustained-release tablets to treat gout-related hyperuricemia was approved by the FDA
Gelonghui, December 6|Haichuang Pharmaceutical (688302.SH) announced that it has received implied permission from the US Food and Drug Administration. The application for the phase II clinical trial of HP501, a urate anion transporter 1 inhibitor independently developed by the company, for the treatment of “gout-related hyperuricemia” has been officially approved. HP501 is a small molecule chemical class 1 innovative drug independently developed by the company. It is an inhibitor of urate anion transporter 1. By inhibiting URAT1 function, it reduces the reabsorption of urate, thereby promoting uric acid excretion and lowering blood uric acid levels.
Haichuang Pharmaceutical (688302.SH): The marketing application for a new drug for deuterium enzalutamide softgels has been accepted
Haichuang Pharmaceutical (688302.SH) issued an announcement. Recently, the company told the National Drug Administration (NMPA)...
Analysis
Price Target
No Data
